tetano
Editor, Senior Moderator
Virus Res
. 2020 Jul 1;198082.
doi: 10.1016/j.virusres.2020.198082. Online ahead of print.
Epitope-based Peptide Vaccines Predicted Against Novel Coronavirus Disease Caused by SARS-CoV-2
Li Lin[SUP] 1 [/SUP], Sun Ting[SUP] 1 [/SUP], He Yufei[SUP] 2 [/SUP], Li Wendong[SUP] 1 [/SUP], Fan Yubo[SUP] 3 [/SUP], Zhang Jing[SUP] 4 [/SUP]
Affiliations
Abstract
The outbreak of the 2019 novel coronavirus (SARS-CoV-2) has infected millions of people with a large number of deaths across the globe. The existing therapies are limited in dealing with SARS-CoV-2 due to the sudden appearance of the virus. Therefore, vaccines and antiviral medicines are in desperate need. We took immune-informatics approaches to identify B- and T-cell epitopes for surface glycoprotein (S), membrane glycoprotein (M) and nucleocapsid protein (N) of SARS-CoV-2, followed by estimating their antigenicity and interactions with the human leukocyte antigen (HLA) alleles. Allergenicity, toxicity, physiochemical properties analysis and stability were examined to confirm the specificity and selectivity of the epitope candidates. We identified a total of five B cell epitopes in RBD of S protein, seven MHC class-I, and 18 MHC class-II binding T-cell epitopes from S, M and N protein which showed non-allergenic, non-toxic and highly antigenic features and non-mutated in 55,179 SARS-CoV-2 virus strains until June 25, 2020. The epitopes identified here can be a potentially good candidate repertoire for vaccine development.
Keywords: B-cell epitope; SARS-CoV-2; Spike protein; T-cell epitope; immune-informatics; vaccine design.
. 2020 Jul 1;198082.
doi: 10.1016/j.virusres.2020.198082. Online ahead of print.
Epitope-based Peptide Vaccines Predicted Against Novel Coronavirus Disease Caused by SARS-CoV-2
Li Lin[SUP] 1 [/SUP], Sun Ting[SUP] 1 [/SUP], He Yufei[SUP] 2 [/SUP], Li Wendong[SUP] 1 [/SUP], Fan Yubo[SUP] 3 [/SUP], Zhang Jing[SUP] 4 [/SUP]
Affiliations
- PMID: 32621841
- DOI: 10.1016/j.virusres.2020.198082
Abstract
The outbreak of the 2019 novel coronavirus (SARS-CoV-2) has infected millions of people with a large number of deaths across the globe. The existing therapies are limited in dealing with SARS-CoV-2 due to the sudden appearance of the virus. Therefore, vaccines and antiviral medicines are in desperate need. We took immune-informatics approaches to identify B- and T-cell epitopes for surface glycoprotein (S), membrane glycoprotein (M) and nucleocapsid protein (N) of SARS-CoV-2, followed by estimating their antigenicity and interactions with the human leukocyte antigen (HLA) alleles. Allergenicity, toxicity, physiochemical properties analysis and stability were examined to confirm the specificity and selectivity of the epitope candidates. We identified a total of five B cell epitopes in RBD of S protein, seven MHC class-I, and 18 MHC class-II binding T-cell epitopes from S, M and N protein which showed non-allergenic, non-toxic and highly antigenic features and non-mutated in 55,179 SARS-CoV-2 virus strains until June 25, 2020. The epitopes identified here can be a potentially good candidate repertoire for vaccine development.
Keywords: B-cell epitope; SARS-CoV-2; Spike protein; T-cell epitope; immune-informatics; vaccine design.